Core Viewpoint - Rongchang Biologics (09995) has seen a nearly 9% increase in stock price, reaching HKD 95.95, with a trading volume of HKD 383 million, following the release of its interim performance report [1] Financial Performance - For the first half of the year, the company reported a revenue of CNY 1.09 billion, representing a year-on-year growth of 48% [1] - The net profit attributable to shareholders was a loss of CNY 450 million, which is a reduction in loss by CNY 330 million compared to the previous year [1] Product Performance - The revenue growth is primarily attributed to the continuous increase in sales of its core products, Taitasip and Vidisizumab, both of which were included in the medical insurance catalog in 2021 [1] - According to Zhongjin Securities, the company's performance in the first half of the year met expectations, with Taitasip's gMG already approved for market launch [1] - The company anticipates submitting applications for market approval for pSS and IgAN in the second half of 2025 [1] - Vidisizumab has been approved for treating second-line HER2-positive breast cancer with liver metastasis, and applications for second-line HER2-low expressing breast cancer and first-line urothelial carcinoma have been submitted [1] - The continuous expansion of indications for core products is expected to accelerate commercialization [1]